IMARC Group’s report titled “Hemostats Market Report by Product (Thrombin Based, Combination Based, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based), Application (Orthopedic Surgery, General Surgery, Neurological Surgery, Cardiovascular Surgery, Reconstructive Surgery, Gynecological Surgery, and Others), Formulation (Matrix and Gel Hemostats, Sheet and Pad Hemostats, Sponge Hemostats, Powder Hemostats), and Region 2024-2032“. The global hemostats market size reached US$ 3.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.8 Billion by 2032, exhibiting a growth rate (CAGR) of 5.73% during 2024-2032.
Factors Affecting the Growth of Hemostats Industry:
- Increasing Surgical Procedures and Trauma Cases:
The hemostats market is primarily driven by the rising number of surgical procedures and trauma cases worldwide. As medical technology advances and populations grow, there is a corresponding increase in the demand for surgical interventions across various medical specialties. Surgical procedures can range from routine operations such as appendectomies and tonsillectomies to complex cardiac surgeries and organ transplants. Additionally, traumatic injuries resulting from accidents, violence, or natural disasters contribute significantly to the need for hemostatic agents. One key driver behind the escalating surgical volume is the aging population. As individuals age, they become more susceptible to chronic illnesses and conditions that may require surgical intervention, such as cardiovascular diseases, cancer, and orthopedic issues. Moreover, advancements in medical treatments have made many surgeries more accessible and safer, prompting more individuals to seek surgical solutions for their health problems.
- Significant Technological Advancements and Product Innovations:
Technological advancements and product innovations play a pivotal role in driving the hemostats market forward. As research and development efforts continue to push the boundaries of medical science, new hemostatic agents with improved efficacy, safety profiles, and ease of use are constantly being developed. These innovations are aimed at addressing the limitations of existing products while meeting the evolving needs of surgeons and patients. One key area of innovation in hemostats is the development of advanced biomaterials. Researchers are exploring novel materials with hemostatic properties, such as synthetic polymers, biodegradable scaffolds, and nanomaterials. These materials can be engineered to exhibit specific properties, such as enhanced clotting capabilities, tissue adherence, and biocompatibility, making them highly suitable for use in surgical procedures. Furthermore, the integration of hemostatic agents with biologically active molecules, such as growth factors and stem cells, holds promise for promoting tissue regeneration and wound healing alongside hemostasis.
- Growing Focus on Blood Loss Management and Patient Safety:
Another significant factor driving the hemostats market is the growing focus on blood loss management and patient safety in surgical settings. Excessive bleeding during surgery can lead to complications such as prolonged operative times, transfusion requirements, organ damage, and even mortality. As a result, there is increasing recognition of the importance of effective hemostasis in improving surgical outcomes and reducing the burden on healthcare systems. One driving force behind this trend is the rising awareness about the risks associated with blood transfusions. Blood transfusions carry inherent risks, including transfusion reactions, infections, and immunological complications. Additionally, blood products are a limited resource, and their availability can be affected by factors such as blood shortages, compatibility issues, and logistical challenges. Therefore, there is a growing emphasis on minimizing blood loss during surgery and employing alternative strategies for managing hemorrhage, such as the use of hemostatic agents.
Leading Companies Operating in the Global Hemostats Industry:
- Arch Therapeutics Inc.
- Baxter International Inc.
- B. Braun Melsungen Aktiengesell
- C. R. Bard Inc.
- GELITA MEDICAL GmbH
- Integra LifeSciences Corporation
- Johnson & Johnson
- Pfizer Inc.
- Stryker Corporation
- Teleflex Incorporated
- Z-Medica LLC
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/hemostats-market/requestsample
Hemostats Market Report Segmentation:
By Product:
- Thrombin Based
- Combination Based
- Oxidized Regenerated Cellulose Based
- Gelatin Based
- Collagen Based
Thrombin based dominates the market due to its crucial role in initiating the coagulation cascade, making it a widely used and effective hemostatic agent in various surgical procedures.
By Application:
- Orthopedic Surgery
- General Surgery
- Neurological Surgery
- Cardiovascular Surgery
- Reconstructive Surgery
- Gynecological Surgery
- Others
General surgery holds maximum number of shares due to the wide range of surgical procedures performed within this specialty, including abdominal, thoracic, vascular, and orthopedic surgeries, among others.
By Formulation:
- Matrix and Gel Hemostats
- Sheet and Pad Hemostats
- Sponge Hemostats
- Powder Hemostats
Matrix and gel hemostats represent the largest segment due to their versatility in effectively controlling bleeding across a wide range of surgical procedures and wound types.
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Global Hemostats Market Trends:
The expansion of ambulatory surgical centers (ASCs) is driving growth in the hemostats market, particularly in regions such as North America and Europe. ASCs offer outpatient surgical services in a convenient, cost-effective, and patient-centered environment, catering to procedures that do not require overnight hospital stays. These centers have gained popularity due to their ability to reduce healthcare costs, improve patient access to surgical care, and enhance efficiency in healthcare delivery. Another significant factor driving the hemostats market is the escalating incidence of chronic diseases worldwide, leading to a higher number of surgeries associated with these conditions. Chronic diseases such as diabetes, cardiovascular disorders, and cancer are prevalent globally and often require surgical interventions for diagnosis, treatment, or symptom management.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 |United Kingdom: +44-753-713-2163
